Jagiellonian University Repository

Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16

pcg.skipToMenu

Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16

Show full item record

dc.contributor.author Biesaga, Beata pl
dc.contributor.author Mucha-Małecka, Anna pl
dc.contributor.author Janecka-Widła, Anna pl
dc.contributor.author Kołodziej-Rzepa, Marta pl
dc.contributor.author Szostek, Sława [SAP20000614] pl
dc.contributor.author Słonina, Dorota pl
dc.contributor.author Kowalczyk, Aleksandra pl
dc.contributor.author Halaszka, Krzysztof pl
dc.contributor.author Przewoźnik, Marcin pl
dc.date.accessioned 2020-01-17T09:19:01Z
dc.date.available 2020-01-17T09:19:01Z
dc.date.issued 2018 pl
dc.identifier.issn 0171-5216 pl
dc.identifier.uri https://ruj.uj.edu.pl/xmlui/handle/item/141740
dc.language eng pl
dc.rights Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa *
dc.rights.uri http://creativecommons.org/licenses/by/4.0/pl/legalcode *
dc.title Differences in the prognosis of HPV16-positive patients with squamous cell carcinoma of head and neck according to viral load and expression of P16 pl
dc.type JournalArticle pl
dc.description.physical 63-73 pl
dc.abstract.en Purpose To evaluate the impact of HPV16 load (VL-the number of virus genome copies per cell) and P16 expression on prognosis of patients with squamous cell carcinomas (SCCs) of head and neck (HN). Materials and methods HPV16 presence was assessed in the group of 109 patients with HNSCCs by quantitative polymerase chain reaction (qPCR). VL (assessed by qPCR) and P16 expression (evaluated by immunohistochemistry) were analysed only in the subgroup of HPV16-positive tumours. These features were correlated with 5-year overall survival (OS) and disease-free survival (DFS). Results HPV16 infection was found in 36 tumours (33.0%). Virus-positive patients had better OS and DFS than those without infection (P = 0.041 and 0.005). Among HPV16-positive HNSCCs, 18 (50.0%) had higher VL (median value > 6764.3 copies/cell) and 25 (73.5%) P16 over expression. The significant differences in OS and DFS (P = 0.008 and 0.004) were noticed according to VL, wherein 100% DFS was found for patients with higher VL. According to P16 expression, significant difference was found only for OS (P = 0.020). In multivariate analysis, VL (P = 0.045; HR = 2.795; CI 0.121-1.060) and the level of smoking (P = 0.023, HR = 2.253; CI 1.124-4.514) were independent factors affecting DFS of HPV16-positive patients. Conclusion On the basis of viral load, it is possible to differentiate prognosis of patients with HPV16-positive HNSCCs. In this subgroup, viral load has stronger prognostic potential than P16 expression. pl
dc.subject.en HNSCCs pl
dc.subject.en HPV16 pl
dc.subject.en viral load pl
dc.subject.en P16 expression pl
dc.subject.en Prognosis pl
dc.description.volume 144 pl
dc.description.number 1 pl
dc.description.points 25 pl
dc.identifier.doi 10.1007/s00432-017-2531-2 pl
dc.identifier.eissn 1432-1335 pl
dc.title.journal Journal of Cancer Research and Clinical Oncology pl
dc.language.container eng pl
dc.affiliation Wydział Lekarski : Zakład Wirusologii pl
dc.subtype Article pl
dc.rights.original CC-BY; inne; ostateczna wersja wydawcy; w momencie opublikowania; 0 pl
dc.identifier.project ROD UJ / OP pl
dc.cm.id 85997
dc.cm.date 2020-01-07
.pointsMNiSW [2018 A]: 25


Files in this item

This item appears in the following Collection(s)

Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa